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Background: Treatment adherence is one of the key factors for achieving optimal clinical 
outcomes. In order to assess costs related to adherence to, and persistence and compliance 
with, disease-modifying therapies (DMTs) in patients with multiple sclerosis (MS), a narrative 
review of the literature was performed. Satisfaction with and preference for DMTs and their 
delivery devices were also assessed, as both can have an influence on patients’ adherence and 
persistence. 
Methods: Electronic databases (MEDLINE, PubMed, Google Scholar, congress proceedings) 
were searched to identify publications analyzing MS costs related to adherence, persistence, 
satisfaction, and preferences for MS treatments. Bibliographic references were hand searched. 
English or Spanish studies published between January 2007 and January 2013 were selected. 
Results: A total of 398 titles were identified, of which 12 met the inclusion criteria. Six stud-
ies evaluated the impact of adherence, persistence, and compliance on treatment costs; four 
publications analyzed satisfaction with DMTs; and two assessed treatment preferences based 
on attributes of the delivery device. Increased adherence and persistence were associated with 
better clinical outcomes, leading to lower relapse risk (odds ratio [OR]: 0.71; 95% confidence 
interval [CI]: 0.59–0.85) and a decrease in health care resource use, such as MS-related hos-
pitalizations (OR: 0.63; 95% CI: 0.47–0.83) and emergency department visits (OR: 0.80; 95% 
CI: 0.60–1.07). This reduction in resource use led to a patient/year total cost reduction (excluding 
DMT costs) of up to 22%. 
Conclusion: This review highlights the importance of ensuring adequate adherence in MS 
patients through treatments and devices better tailored to patients’ needs that could enhance 
clinical outcomes and reduce MS costs. Understanding the factors underlying satisfaction 
and compliance with treatment and patients’ preference for certain therapies could help in the 
development of strategies that can improve adherence.
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Introduction
Multiple sclerosis (MS) is an inflammatory, neurodegenerative disease of the central 
nervous system that results in demyelination and transaction of axons in the brain, 
spinal cord, and optic nerves.1 The clinical disease course is variable, usually starting 
with reversible episodes of neurological disability in the third or fourth decade of life, 
then transforming into a disease marked by continuous and irreversible neurological 
decline by the sixth or seventh decade.1 This clinical course may be considered the 
expression of two phenomena: relapses of acute neurological symptoms, which end 
in partial or complete remission; and progression, which refers to the steady and irre-
versible worsening of signs and symptoms.2,3
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MS affects about 2 million–2.5 million people world-
wide.4 In Europe, the prevalence tends to be higher in the 
United Kingdom and in Nordic countries, ranging from 
96/100,000 to more than 200/100,000, compared with the 
situation in Central European countries, where prevalence 
ranges from 62/100,000 to 128/100,000.5 According to a 
recent analysis of MS incidence trends in the European 
Economic Area, the incidence of MS ranges from 1.12–6.96 
per 100,000 persons, is higher in females, and triples with 
increasing latitude.6 
Due to the early age of disease onset and its progressive 
disabling course, the economic burden of MS is considerable. 
Moreover, taking into account that MS affects people in the 
most productive stage of their lives, affecting patients’ and 
caregivers’ health-related quality of life and productivity,7 the 
disease also carries an important social burden.8 In a recent 
burden-of-illness study conducted in five European countries 
(France, Germany, Italy, Spain, and the United Kingdom), the 
mean yearly cost per patient with MS increased with disease 
severity: between €13,534 and €22,461 for patients with mild 
MS (Expanded Disability Disease Scale [EDSS] score 3); 
between €28,524 and €43,948 for moderate MS (EDSS 4–6.5); 
and between €39,592 and €65,395 for severe MS (EDSS 7).9 
Relapses were positively associated with increase in cost.7 
There is no cure for MS at present and available disease-
modifying therapies (DMTs) aim to reduce relapses or slow 
down disease progression.10 In these strategies, adherence is 
key to obtaining optimal clinical outcomes.11,12 Poor adherence 
is a problematic and challenging issue in the management 
of many chronic diseases and is associated with significant 
consequences in both clinical and economic outcomes.11 
Adherence to treatment in patients with chronic diseases is 
as low as 50%, which can decrease to 40% in patients with 
MS.13 The main causes of nonadherence reported by patients 
are forgetting to take a dose, injection-site reactions (ISRs), 
fatigue due to the medication, dislike of the administration 
route, and side effects.13 
Inadequate adherence represents a significant burden, not 
just to patients, but also to the health care system and society. 
Although different studies have shown the importance of 
treatment adherence, persistence, and compliance in reduc-
ing relapse rates in patients with MS,11 information on their 
impact on MS costs is scarce. In order to assess costs related 
to patient adherence to – and persistence and compliance 
with – DMTs, a literature review was performed. Addition-
ally, satisfaction with and preferences for DMTs and their 
delivery devices were assessed, as they can affect patients’ 
adherence, persistence, and compliance. 
Methods
A comprehensive review of the literature on the costs related 
to adherence and persistence in MS patients taking DMTs 
and patient-reported outcomes (PROs) related to MS treat-
ment (satisfaction and preferences) was performed using 
information from electronic databases covering a period 
of 6 years (January 2007–January 2013). This time period 
was selected in order to identify the most up-to-date and 
recent publications and to obtain accurate insight into cur-
rent treatment options for MS from the patient perspective. 
In recent years, new diagnostic criteria and techniques, as 
well as novel treatments, have compelled us to readdress 
and reappraise our understanding and management of MS.14 
For this reason, this review focuses on publications from the 
last 6 years. The source of peer-reviewed publications was 
MEDLINE/PubMed, using the search terms summarized in 
Table S1. Grey literature (Google Scholar) and congress pro-
ceedings (annual congresses of the International Society of 
Pharmacoeconomics and Outcomes Research, the European 
Committee for Treatment and Research in Multiple Sclero-
sis, and the European Federation of Neurological Societies) 
were searched. The bibliographic references of the reviewed 
publications were also checked.
Original articles, reviews, and congress proceedings in 
English or Spanish, published between January 2007 and 
January 2013 in Europe, North America, or Australia were 
included in the present review if they reported cost results 
related to adherence persistence and compliance in MS 
patients, or MS patients’ satisfaction with and preference 
for DMTs and treatment administration devices. The review 
excluded cost estimations and economic evaluations of 
concrete active treatments; studies that reported adherence 
measures not related to MS costs; studies related to satisfac-
tion with or preferences for non-DMTs; and letters to the 
editor, editorials, expert opinion pieces, and case studies. 
The study selection was performed by two independent 
researchers (MC and SP) and discrepancies were solved 
by consensus.
The methodological quality of the studies was appraised 
by assigning a level of evidence and recommendation 
based on the Centre for Evidence-Based Medicine (CEBM) 
criteria.15 Journal impact factor (2012) and the number of 
citations (Web of Science16 and Google Scholar17) were 
used to assess the probability of published results reaching 
a sizeable audience.
For cost studies, all cost results were converted to Euros 
and updated to 2013 values to facilitate the comparison of 
findings among publications. 
Patient Preference and Adherence 2014:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1655
Patient-reported outcomes and MS cost: a literature review
Results
A total of 398 titles were initially identified, of which 311 
were excluded as they were duplicates or not relevant. After 
application of the inclusion/exclusion criteria, 12 publications 
were found to contain original information on MS-related 
costs associated with adherence and persistence in patients 
on DMTs, and were therefore included in the present review 
(Figure 1). 
Four retrospective cohort studies, one systematic review, 
and one decision-analytic model, all performed in the United 
States between 2010 and 2013, were reviewed. Moreover, in 
order to understand the determinants of patient satisfaction 
with therapeutic alternatives that may have a great impact 
on adherence, compliance, and persistence with therapy over 
time, six other studies on satisfaction with and preferences 
for DMTs and their devices were included. Five studies were 
performed in Europe (two in Switzerland and one each in 
Germany, France, and the United Kingdom), and one in the 
USA between 2007 and 2012. A description of the selected 
studies is summarized in Table 1. Most of the studies had 
a level of evidence of 2C or lower, with a CEBM recom-
mendation of grade B, which implies limited methodological 
consistency.
In all selected studies, patient adherence to DMTs was 
assessed using the medication possession ratio (MPR), 
calculated as the total days of medication supply dispensed 
divided by the number of days that the patient should have 
been taking the medication.18 Provided that the number of 
days’ supply remains constant, the longer the duration of time 
between the first and last prescription, the lower the MPR. 
Patients with an MPR of 80% or higher were considered to 
be adherent. Medication persistence was defined as the time 
duration from initiation to discontinuation of therapy.19
During the development of the present study, a systematic 
review assessing the published data on adherence to DMTs 
and its impact on both clinical and economic outcomes from 
the patient and payer perspective was published (January 
2013).20 This publication included 24 studies related to DMT 
adherence. The authors reported that adherence to DMTs 
ranges from 21%–88%, and that there is a numerically 
greater risk of MS relapses or disease progression in patients 
who are nonadherent to treatment (statistically significant 
in two of four studies). In addition, two studies showed a 
statistically significant reduction in the use of inpatient or 
emergency department services and total MS-related medical 
costs among patients adherent to treatment compared with 
patients who were nonadherent. The authors concluded that, 
because of the chronic nature of MS, long-term adherence 
to DMTs can be challenging. The authors also found that 
adherence was higher in studies with prospective rather than 
Figure 1 Flow-chart summary of literature search. 
Abbreviations: DMT, disease-modifying therapy; n, number.
12 publications reviewed
75 full text articles excluded:
– No cost estimation (n=48)
– Cost not related to adherence/
  persistence/compliance (n=13)  
– Cost-effectiveness or cost-utility 
 analysis comparing treatments 
 (n=8) 
– Not related to DMTs or their 
 administration devices (n=6)
87 publications retrieved 
for full-text reading
311 duplicated and excluded
based on title/abstract
384 titles identified
through PubMed
searching
14 titles identified through 
congress proceedings 
and hand search
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retrospective designs. Unlike the present study, this publica-
tion focused only on patients’ adherence to therapy.
Clinical outcomes related to adherence 
to and persistence with DMTs
Relapses are the hallmark of MS, with approximately 80% 
of cases diagnosed as relapsing–remitting MS at onset, and 
relapses play an important role in determining subsequent 
prognosis and the development of disability.21 Some authors 
have reported that up to 49% of patients with relapsing–
remitting MS exhibit residual deficits on the EDSS after 
relapses, and have suggested that therapies that are effective 
in reducing relapse frequency and/or severity could slow or 
prevent worsening of the disability if initiated prior to disease 
onset or early in the disease course.22
DMTs have the potential to alter the natural history of 
MS by reducing the frequency and severity of relapses and 
slowing disability progression. However, patients who do 
not adhere to or persist with therapy are unlikely to receive 
the full benefits of treatment.23 
Two of the studies that evaluated the association between 
adherence rates and MS-related costs determined the clinical 
outcomes related to adherence.24,25 Both studies reported that 
adherent patients initiating DMTs were significantly less 
likely to experience relapses, indicating control of symptoms 
or improvement in the first 12 months of follow-up (odds 
ratio [OR]: 0.71; 95% confidence interval [CI]: 0.59–0.85; 
with adherent patients defined as having an MPR of 80%).24 
As Figure 2 shows, in both studies patients who were adher-
ent to DMTs had a lower rate of severe relapses compared 
with nonadherent patients (27.3% versus 34.7%; P0.001;24 
12.5% versus 19.5%, respectively; P=0.020025). Therefore, 
these authors suggested that adherence to therapy could 
be a key factor in improving patient clinical outcomes, as 
observed via lower rates of MS-related symptoms in the 
form of relapses.24
MS costs related to adherence 
to and persistence with DMTs
The impact of adherence to DMTs on economic outcomes 
among MS patients was assessed in two retrospective cohort 
studies. The first study determined the impact of treatment 
adherence on MS-related medical resource use (inpatient, 
emergency department visits, MS relapses) and medical 
costs,24 whereas the second study compared rates of severe 
relapses and total direct and indirect costs over a 2-year 
period in US-based employees with MS who were adherent 
and nonadherent to DMTs.25
In both studies, the lower incidence of relapses – in par-
ticular, severe relapses – resulted in a significant decrease 
in health care resource use: between 35%25 and 40%24 in 
MS-related hospitalizations and between 20%25 and 40%24 
in MS-related emergency department visits. Adherent 
patients were less likely to have MS-related hospitalizations 
(OR: 0.63; 95% CI: 0.47–0.83) and MS-related emergency 
department visits (OR: 0.80; 95% CI: 0.60–1.07) compared 
with nonadherent patients (Figure 2). These results suggest 
that adherence to therapy may be a key driver in improving 
patient outcomes.24 
In addition to a reduction in the use of resources, 
medical expenditures were also lower for adherent patients 
when compared with nonadherent patients. Over a 2-year 
period, DMT-adherent patients had incurred significantly 
lower all-cause inpatient costs (mean [standard deviation 
Figure 2 Comparison between the percentage of adherent and nonadherent patients with at least one severe multiple sclerosis relapse, inpatient visit, and emergency 
department visit over 1 year. 
Note: Data from Tan et al24 and ivanova et al.25
Abbreviations: MS, multiple sclerosis; eD, emergency department.
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{SD}]: €648.71 [€3,753.74] versus €1,740.88 [€6,127.27]; 
P=0.0018]) and all-cause emergency department costs 
(€147.82 [€430.79] versus €242.42 [€592.96]; P=0.0044], 
compared with nonadherent patients).25 When total direct 
costs (excluding DMT costs) were assessed, both all-cause 
direct costs (mean [SD]: €9,337.82 [€11,816.55] versus 
€10,312.19 [13,186.48]; P=0.8753) and MS-related direct 
costs (€4,824.58 [€7,208.43] versus €5,145.82 [€8,240.16]; 
P=0.4858) were lower, albeit not significantly, in adherent 
patients compared with nonadherent patients.25 Indirect costs 
were also lower, but not significantly, in adherent patients 
compared with nonadherent patients (mean [SD]: €3,012.15 
[€7,745.70] versus €3,522.44 [€8,056.07]; P=0.9010). Other 
authors reported that adherent groups had on average 22% 
(95% CI: 8%–34%) less MS-related medical costs than 
nonadherent groups during a 12-month period (€2,779.91 
[95% CI: 2,505.12–3,084.11] versus €3,575.92 [95% CI: 
3,148.26–4,062.80]).24 
A third study reported how changes in MPR affected the 
probability of MS relapses and total costs and MS-related 
charges among patients treated with glatiramer acetate.26 
Patients achieving MPRs of 50% or higher had significantly 
lower inpatient and emergency department expenditures com-
pared with patients with lower MPRs,26 incurring €2,665.57 
(P=0.002), €851.93 (P=0.004), and €75.89 (P=0.006) lower 
inpatient, outpatient, and emergency department costs, 
respectively, than patients with MPRs of less than 50%. 
The impact of adherence on total cost became greater as the 
MPR threshold increased. Patients with an MPR threshold 
of at least 95% reached incremental benefits of €6,728.72 
(P0.001), €10,297 (P=0.001), and €87.51 (P=0.05) in 
inpatient, outpatient, and emergency department costs, 
respectively.26 
The fourth study evaluated the clinical and economic 
impact of specialty care management programs designed 
to increase adherence among patients with MS. Results 
showed that implementation of a special care management 
program during 12 months, using educational materials and 
reminder calls, led to an increase in the adherence ratio of 
up to 18% (95% CI: 16%–19%) and longer persistence with 
treatment (306.1 days versus 246.9 days; P0.001) among 
participants with respect to controls.27 Participants had both 
lower hospitalization rates (7.1% versus 12.0%; P0.001) 
and lower hospitalization risk (OR: 0.51; 95% CI: 0.39–0.67) 
than controls. As a consequence, the nonpharmacy costs 
decreased by €217.12 per patient during 1-year of follow-up, 
but increased by €1,263.25 per patient in the control group. 
Nevertheless, the pharmacy cost increase due to improved 
adherence and persistence caused the total health care cost 
to increase by 21%, suggesting that the global economic 
benefit of this program should be assessed on a longer time 
horizon.27 
A decision-analytic model designed to determine the eco-
nomic impact of DMT persistence on 2-year nonpharmacy 
medical costs, using persistence rates and health care resource 
use and costs from published literature, showed that patients 
initiated on intramuscular interferon (IFN) β-1a had 8.9% 
lower annual medical costs (€6,104.89) than did patients 
initiated on subcutaneous (SC) IFN β-1b (€6,697.89) and 
1.7% lower costs than those on SC IFN β-1a (€6,210.94).28 
These results indicated that persistence with DMTs was an 
important factor in overall medical costs for patients with MS. 
For this reason, efforts to improve persistence with DMTs 
could lead to lower medical costs for health care systems.28 
PROs related to adherence: treatment 
satisfaction and preferences for attributes 
of DMT delivery devices
Inadequate adherence reduces the effectiveness of treatment, 
which can lead to relapses and deterioration in general health. 
Different studies have shown a positive association between 
treatment satisfaction and adherence, compliance, or persis-
tence, with the most satisfied patients being the most adher-
ent, compliant, or persistent.29 Consequently, understanding 
patient perceptions of and preferences for therapies may help 
in developing strategies to improve adherence, compliance, 
and persistence with treatment. Six studies were reviewed to 
identify the determinants of patient satisfaction that may have 
an impact on adherence, compliance, and persistence. 
Determinants of discontinuing MS 
treatment 
Three studies investigated the reasons for discontinuing MS 
treatment. The first, performed in Germany, estimated the 
compliance, satisfaction, and adverse effects of DMTs.30 
The second, a French study, assessed patient perceptions 
and awareness of MS and its treatment, treatment adherence, 
and impact of treatment on quality of life and daily living.31 
The third was a 2-year, observational, multicenter study 
conducted in Switzerland (the Swiss MS Skin Project) that 
evaluated the relative frequency and severity of ISRs associ-
ated with injectable DMTs.32
In Germany, about 75% of patients were compliant with 
DMTs for more than 2 years. Only 4.2% reported discon-
tinuing treatment during the first 3 months, 9% during the 
first year, and 11.3% by 2 years of treatment. During a period 
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of less than 4 months, treatment was suspended once in 75.7% 
of patients, twice in 8.5%, thrice in 2.6%, and more than three 
times in 3.4%. Further, treatment had been changed once in 
75.3% of patients, twice in 10.9%, thrice in 10.5%, and more 
than three times in 3.3%.30 Overall treatment satisfaction 
with DMTs among German patients with MS was high to 
moderate (score: 2.1–2.7, where 1=highest satisfaction and 
6=worst satisfaction).30
In both the German and French studies, patients reported 
that the main reasons for discontinuing DMTs were adverse 
effects (26.4% and 54%, respectively),30,31 physician’s recom-
mendation (24.7%),30 or a lack of treatment effect (23.3% and 
46%).30,31 However, regression analyses of factors influencing 
treatment compliance performed in Germany revealed that 
only the use of a wheelchair and the secondary progressive 
course of MS significantly predicted a lower compliance 
with treatment.30 
The Swiss MS Skin Project reported that ISRs were 
one of the most common reasons for patients discontinu-
ing or switching therapy (30.8% at the first evaluation and 
17.9% after 1 year).32 The authors recommended selecting 
therapies associated with a lower ISR risk and educating 
patients on strategies to minimize the occurrence of ISRs, 
with the aim of improving treatment adherence and thus 
increasing the chance of optimal MS treatment outcomes 
over the long term.32
To increase compliance and satisfaction with treatment, 
adequate information about the disease, therapeutic options, 
handling of medications, and side effects and their manage-
ment were necessary.30 In France, less than half (42.6%) of 
patients with MS reported that they had been well informed 
about their disease, while 34.7% reported that they had been 
well informed about their treatment. Nearly half of patients 
(44%) were involved in the treatment decision-making pro-
cess and listed efficacy (42.2%), injection frequency (27.8%), 
and adverse events (15.6%) as the most important factors 
when choosing a treatment over another.31
Patient satisfaction with delivery device
MS patients’ satisfaction with their current injection device 
and their reaction to a new autoinjector were investigated in a 
multicountry study performed in Canada, France, Germany, 
Italy, Spain, and the US.33 The results showed that less than 
half of patients were satisfied with their current delivery 
device (40%, defined as 8–10 points on a 10-point scale 
where 0=“not at all satisfied” and 10=“very satisfied”). The 
proportion of “very satisfied” patients was highest among 
those using an autoinjector device (46%), intermediate 
in patients using a prefilled syringe (39%), and lowest in 
patients using a syringe and vial (23%). Of the respondents, 
66% always self-injected the medication, 19% always had 
someone else perform the injection, and the remaining 15% 
sometimes self-injected and other times had someone else 
do it. The reasons for not self-injecting were physical (the 
most common being “difficulty with injecting” [57%] and 
pain at injection being infrequent [10%]) or psychological 
(including dislike of looking at needles [39%], the thought 
of injection [37%], and lack of confidence in one’s ability 
to inject correctly [32%]).33 
When those patients were asked to consider a new auto-
injection device, they listed the most positive features as: 
the possibility of adjusting the speed and depth of injection 
(39%); a dosing log for reliable dose monitoring (38%); eas-
ily accessible injection areas (34%); a simple uncomplicated 
procedure (29%); and a hidden needle (29%). Overall, 96% 
of respondents had identified a benefit that would encourage 
them to ask their nurse or physician about the new device, 
and 23% considered that the new device had no drawbacks 
at all.33 These results suggest that technologies designed to 
help patients overcome physical and psychological barri-
ers to self-injection may contribute to improved treatment 
adherence.33
Patient preferences for MS health states 
and for attributes of MS treatments
Two publications referred to discrete choice experiments 
(DCE) that evaluated preferences for treatment attributes and 
reviewed health states of patients with MS. The first DCE 
estimated the willingness of patients to accept life-threatening 
adverse-event risks in exchange for improvements in their 
MS-related health outcomes.34 Five treatment attributes were 
selected: two measures of treatment efficacy (reduction in 
the number of relapses experienced in the next 5 years, and 
delay [in years] of disability progression); and three mortality 
risks (death or severe disability from progressive multifocal 
leukoencephalopathy [PML], death from liver failure, and 
death from leukemia). The treatment attribute that had the 
largest overall effect on preferences was years to progression, 
followed by the risk of PML, whereas the attribute with the 
smallest overall effect was the frequency of relapses over 
5 years. Patients said that they were willing to assume associ-
ated mortality risks as high as 0.39% (95% CI: 0.32%–0.46%) 
for liver failure, 0.38% (95% CI: 0.32%–0.43%) for PML, 
and 0.48% (95% CI: 0.39%–0.58) for leukemia in order to 
obtain a relevant clinical benefit, defined as a 5-year reduction 
in MS relapses from 4 years to 1 year and a slowing down of 
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MS progression from 3 years to 5 years. Thus, most patients 
with MS indicated that they were willing to accept risks in 
exchange for clinical efficacy. 
The second DCE, performed in the UK, assessed MS 
patients’ preferences for the attributes of injection devices.35 
Choice sets of attributes identified in the literature – including 
ease of use, comfort of use, additional functions, needle 
visibility, practicality, and efficacy (expressed in terms of 
prevention of increasing disability level) – were presented 
as pairs of hypothetical treatments. Participants were asked 
to decide which of the two treatments they preferred. Results 
determined that efficacy was the attribute with the highest 
impact on patient preference (OR: 0.117 for a device that was 
likely to result in disease progression by one level on the MS 
scale; P0.001). These patients placed great importance on 
device comfort and practicality, preferring compact, ready-
to-use, nonrefrigerated devices that could be easily placed 
on the injection site. 
Discussion
This review of the literature on adherence to MS treatments 
and disease costs shows the scarcity of studies addressing 
this issue. Nonetheless, the available publications allow us 
to anticipate the magnitude in cost reduction that can be 
achieved by slight improvements in treatment adherence. 
Nonadherence to medication is a significant problem 
in chronic disease management,36 and patients who do not 
adhere to or persist with therapy are unlikely to receive 
the full benefits of treatment, leading to worse clinical 
outcomes.23 As this review shows, patients who are adherent 
to DMTs are less likely to experience MS relapses than those 
who are nonadherent. Regardless of its effects on long-term 
disability, preventing MS relapses has positive effects on 
patients’ short-term quality of life and functioning.9 When 
relapses occur, treatment choice depends on relapse severity 
and may include additional visits to outpatient services and 
inpatient care.37 Lage et al38 observed that severe MS relapses 
requiring hospitalization were associated with high medical 
costs, and that nonadherence to DMTs was strongly associ-
ated with an increased number of severe relapses. 
Although treatment characteristics are key to adherence 
among patients with MS, adherence is a much more complex 
phenomenon. Mood or anxiety disorders increased by almost 
five times the likelihood of exhibiting adherence problems 
with DMTs compared with the absence of a psychiatric 
diagnosis.35 Poor adherence has also been associated with 
memory difficulties, anxiety, depression, neuroticism, and 
low conscientiousness.39 The design of the reviewed studies 
also influenced adherence and cost results. Retrospective 
studies have been reported to draw less satisfactory adherence 
estimates than prospective studies.20 Most studies reviewed 
had a retrospective design, suggesting that there may be 
greater differences in costs attributable to adherence among 
patients with MS.
Preventing patients from having severe relapses by 
improving adherence to treatment also suggests fewer hos-
pital admissions and emergency department visits, which are 
the most expensive medical resources. As a consequence, 
the nonpharmacological costs of the disease decrease sig-
nificantly. Findings of this nature are common with other 
chronic, disabling, progressive diseases that require sus-
tained, long-term treatments, for which injectable formula-
tions become paramount. In this sense, a study that assessed 
the impact of adherence in patients with rheumatoid arthritis 
suggested that even though DMTs increased pharmacy costs, 
this cost increase was partially offset by a decrease in other 
sanitary costs (related to exacerbations and hospitalizations) 
and by improvements in health-related quality of life and 
treatment satisfaction.40 
The positive correlation between nonadherence, adverse 
outcomes, and medical costs described in this review has also 
been documented for other chronic diseases. A retrospec-
tive analysis of women with osteoporosis indicated that low 
adherence (MPR 50%) was associated with a 37% higher 
likelihood of fracture, with 12%–18% higher all-cause medi-
cal costs and 34%–59% more all-cause hospitalizations.41 
A study that examined the relationship between medication 
adherence and the use and cost of health services in patients 
with four chronic vascular conditions (congestive heart 
failure, hypertension, diabetes, and dyslipidemia) found 
that although adherent patients incurred higher pharmacy 
spending than those who were nonadherent, annual medical 
spending was significantly lower for adherent patients.42 As 
anticipated, improvements in medication adherence increase 
pharmacy spending. Nevertheless, the additional pharmacy 
spending incurred from adherence was more than offset by 
the medical savings gained as a result of reductions in hos-
pitalization and emergency department use.42 
It is known that the introduction of DMTs increases phar-
macological spending. Nonetheless, these therapeutic options 
are associated with improvements in quality of life and better 
clinical outcomes that can be translated into long-term sav-
ings. A German study that compared the cost composition 
of rheumatoid arthritis before and after the introduction of 
biological drugs showed that although pharmaceutical costs 
increased from €550 to €1,580 (P0.001), overall costs 
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before and after the introduction of tumor necrosis factor 
blockers were comparable (€4,280 to €3,830; P=0.3).43 The 
decrease in hospitalization and productivity costs associated 
with better clinical outcomes is promising in terms of future 
long-term cost savings, suggesting that initial increased phar-
macological costs may be offset over the long term. 
Preferences for treatments have been shown to affect treat-
ment satisfaction,44 and improvement in treatment satisfac-
tion has been associated with greater treatment adherence.29 
Some authors have suggested that improving the convenience 
and acceptability of a treatment by using best-suited drug-
delivery devices is another approach to improve adherence 
to MS treatment.45 Ascertaining the attributes that patients 
most value would improve treatments and devices in a 
way that could increase patient adherence and satisfaction. 
According to the reviewed publications, the attributes that 
are reported as more preferable to patients when considering 
DMTs are treatment efficacy, administration frequency, and 
ISRs. Similar to other findings on the preferences for device 
characteristics, patients tended to assign greater importance 
to minor efficacy gains while gaining benefits on the admin-
istration of treatments.46 In line with these results, a recent 
study suggests that the provision of information at the outset 
of therapy may improve adherence in patients with MS, with 
high-quality information and well-being on treatment being 
the main determinants of persistence with SC IFN β-1a.47
In concordance with other publications, most patients 
with MS indicated that they would be willing to accept risks 
in exchange for clinical efficacy. Patients with cancer were 
more willing to undergo intensive therapy with a small likeli-
hood of benefit than were physicians or the general public, 
suggesting that changes in patients’ health status may affect 
their treatment preferences as they become more willing to 
tolerate a diminished state of health.48 Fried et al49 found that 
patients who experienced a decline in instrumental activities 
of daily living were more likely to rate more severe functional 
disability as an acceptable outcome of therapy than those 
who did not experience such a decline. 
The results of this review have to be interpreted in 
the context of its limitations – namely, the small number 
of papers identified. Despite our comprehensive search, 
there may have been relevant papers in languages other 
than English or Spanish, or that may have been indexed in 
databases other than PubMed, which we did not identify. 
The weak consistency of the methodology in most of the 
reviewed studies can be explained by their observational and 
exploratory design, which tends to translate into lower rates 
of methodological quality when an assessment tool, such as 
the CEBM level of evidence, is applied. Most reviewed stud-
ies involved North American or European populations, thus 
reflecting disease characteristics and viewpoints of patients 
in developed countries with presumably similar socioeco-
nomic levels. A broader scope encompassing PROs and MS 
costs in developing countries may need to be considered to 
describe the disease worldwide. MS is a costly disease and 
the health care system differences in developing countries 
may distinctively hamper patient adherence to and persis-
tence with treatment. 
Although these results should not be generalized and 
are not necessarily applicable across different countries 
and within diverse health care scenarios, the review offers 
a glimpse into the importance of adequate adherence in MS 
patients to manage the costs associated with the disease and 
highlights the potential benefits provided by new technolo-
gies, designed to support patient engagement by providing 
easily accessible information to aid disease management 
decisions, allowing patients to record and share their 
experience about important physical and psychological/
emotional aspects of their disease, as well as optimizing 
the clinic time that patients and physicians have together. 
Further insight into MS management options, their economic 
impact, and their value from the patient perspective is needed 
across cultures.
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Table S1 PubMed search terms, strategies, and title identified
Search terms Title identified
“Multiple sclerosis” AND “adherence” AND “cost” 26
“Multiple sclerosis” AND “compliance” AND “cost” 31
“Multiple sclerosis” AND “persistence” AND “cost” 8
“Multiple sclerosis” AND “route of administration” AND “compliance” 23
“Multiple sclerosis” AND “adherence” AND “device” 13
“Multiple sclerosis” AND “route of administration” AND “adherence” 48
“Multiple sclerosis” AND “device” AND “cost” 18
“Multiple sclerosis” AND “device” AND “compliance” 12
“Multiple sclerosis” AND “route of administration” AND “persistence” 9
“Multiple sclerosis” AND “route of administration” AND “cost of disease” 13
“Multiple sclerosis” AND “route of administration” AND “disease burden” 11
“Multiple sclerosis” AND “treatment satisfaction” 134
“Multiple sclerosis” AND “preferences” 27
“Multiple sclerosis” AND “willingness to pay” 11
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